ICRAD NEOVACC Novel strategies to enhance vaccine immunity in neonatal livestock

• Forschungsstelle: BLV
• Projektnummer: 1.21.11

Schlüsselwörter (Englisch)

Vaccines, neonatal immunisation, maternal antibody, bovine respiratory syncytial virus, porcine
reproductive and respiratory syndrome virus

Kurzbeschreibung (Englisch)

Infectious diseases of livestock continue to cause a major financial impact globally, threatening food security and public health. Disease control measures comprise a combination of biosecurity with both preventative and therapeutic treatments. However, vaccination represents the most highly cost-effective tool to prevent, manage and even eradicate diseases. Maternally derived antibodies (MDA) play a critical role in protecting neonatal livestock against infectious diseases during their early life. However, MDA can dampen immune responses of neonates to vaccination through a number of distinct mechanisms, including the neutralisation of live attenuated vaccines and the inhibition of neonatal B cell responses. Thus, as MDA wanes immunised animals remain vulnerable to pathogen challenge. In this project, we will test vaccine strategies designed to enhance immune responses in neonatal animals with MDA. Our state-of-the-art approaches to this challenge span improved immunogen design, antigen delivery configuration and immunopotentiators. We will focus on two major endemic viral diseases: bovine respiratory syncytial virus (BRSV) in cattle and porcine reproductive and respiratory syndrome virus (PRRSV) in pigs, for which the consortium has developed preliminary tools and knowledge of strategies to counteract different mechanisms of MDA interference. BRSV is estimated to cause 14-71% of bovine respiratory disease outbreaks globally and PRRSV is considered the most economically important disease affecting the global pig industry with estimated losses in Europe exceeding €1.5 billion p.a. In both these infections, MDA interfere with neonatal vaccination leading to high vulnerability at the time of weaning or feedlot/fattening where MDA are low and active immunity is not yet in place. The project is structured with three complementary work-packages (WP): WP1: Designing BSRV immunogens to exploit differences in antibody repertoires between adult and neonatal cattle. We will identify epitopes on the pre-fusion (preF) protein that distinctly targeted by neonatal and adult antibody repertoires. Epitope-scaffold antigens will be anchored on N-nanorings, that are immunogenic carriers easy to produce in bacteria at low cost. These will be evaluated in MDA+ calves for protection against an experimental BRSV challenge. WP2: A DNA vaccine-based approach against PRRSV to counteract MDA interference. We will generate DNA vaccines where PRRSV antigens are fused to XCL1, anti-MHC-II scFv, as targeting moieties that we have shown enhance immunogenicity. We will then test if a targeted DNA prime/MLV boost vaccine strategy enhances cell mediated and Ab responses and increase vaccine efficacy in MDA+ piglets. Complimentary in vitro experiments will be conducted using DC-targeted antigens to understand how they counteract the MDA-negative effect on B-cell responses. WP3: Engineering immune checkpoint inhibitors to enhance neonatal responses to vaccination. Immune checkpoints are natural regulators of the immune system, crucial for maintaining self-tolerance and reducing immunopathological responses. Immune checkpoint inhibitors are highly effective cancer immunotherapeutics and are emerging as a novel class of adjuvants for prophylactic immunization. We will evaluate whether genetically engineering PRRS MLV to express peptide-based ICIs will potentiate vaccine responses of MDA+ piglets resulting in enhanced protection. The outputs from this project will directly benefit the development of improved vaccines against these two key diseases but also as a concept since the approaches may be exploited in the context of other pathogens, livestock species and humans.

Projektziele (Deutsch)

In this project, we will develop and test vaccine strategies designed to enhance immune responses in neonatal animals with Maternally derived antibodies (MDA).

Weiteres Vorgehen (Deutsch)

1.21.11  ICRAD NEOVACC Novel strategies to enhance vaccine immunity in neonatal livestock

Entscheid Umsetzungsziele Mai 2021: In this project, we will develop and test vaccine strategies designed to enhance immune responses in neonatal animals with Maternally derived antibodies (MDA).

14.06.2021: Novel strategies to enhance vaccine immunity in neonatal livestock (Correia): ICRAD Projekt. Vertragsentwurf ging am 06.05.2021 zum Antragsteller, eine Antwort ist weiterhin ausstehend.
Umsetzungsziele: Antragsteller: “in this project, we will develop and test vaccine strategies designed to enhance immune responses in neonatal animals with Maternally derived antibodies (MDA)“; BLV: Publikation in der Fachpresse. (270. FoKo/mvo)

25.01.2023: Zwischenbericht des Konsortiums ist eingegangen. Dem Forscher sind unseren Abläufe völlig fremd; gre wird das Gespräch (nochmals) suchen.
factsheet mid term NEOVACC.pdf Die BeEx genehmigt diesen Bericht.(289. Sitzung der Plattform Forschung/mvo)

27.05.2024:  der Zwischenbericht wurde genehmigt; die Tranche vom letzten Jahr wird noch ausbezahlt. (304. FoKo / ruo)

09.12.2024:  EU-Schlussbericht ist eingegangen. Das Datenblatt wurde auf den 12.12.2024 versprochen. In Stv. der BeEx, die abwesend ist, wird gre die Prüfung des Schlussberichtes vornehmen. Die Schlussrechnung erfolgt noch aufs Budget 2024. (310 FoKo / ruo)

23.01.2025 EU-Schlussbericht ist eingegangen. Das Datenblatt ist eingegangen. gre hat den Bericht genehmigt. Es wird kein Wissenstransfer stattfinden, da das Thema nicht ausreichend in den Kompetenzbereich des BLV fällt. Somit erhält das Projekt den Status erledigt. (311. FoKo / ruo)